JPWO2021237143A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2021237143A5
JPWO2021237143A5 JP2022570474A JP2022570474A JPWO2021237143A5 JP WO2021237143 A5 JPWO2021237143 A5 JP WO2021237143A5 JP 2022570474 A JP2022570474 A JP 2022570474A JP 2022570474 A JP2022570474 A JP 2022570474A JP WO2021237143 A5 JPWO2021237143 A5 JP WO2021237143A5
Authority
JP
Japan
Prior art keywords
composition
day
salt
25hc3s
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022570474A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023527153A (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/033743 external-priority patent/WO2021237143A1/en
Publication of JP2023527153A publication Critical patent/JP2023527153A/ja
Publication of JPWO2021237143A5 publication Critical patent/JPWO2021237143A5/ja
Pending legal-status Critical Current

Links

JP2022570474A 2020-05-22 2021-05-21 非アルコール性脂肪性肝炎(nash)の処置 Pending JP2023527153A (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US202063029361P 2020-05-22 2020-05-22
US63/029,361 2020-05-22
US202063030207P 2020-05-26 2020-05-26
US63/030,207 2020-05-26
US202063113116P 2020-11-12 2020-11-12
US63/113,116 2020-11-12
US202163146555P 2021-02-05 2021-02-05
US63/146,555 2021-02-05
PCT/US2021/033743 WO2021237143A1 (en) 2020-05-22 2021-05-21 Treatment of non-alcoholic steatohepatitis (nash)

Publications (2)

Publication Number Publication Date
JP2023527153A JP2023527153A (ja) 2023-06-27
JPWO2021237143A5 true JPWO2021237143A5 (enExample) 2024-05-28

Family

ID=78707644

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022570474A Pending JP2023527153A (ja) 2020-05-22 2021-05-21 非アルコール性脂肪性肝炎(nash)の処置

Country Status (11)

Country Link
US (1) US20230181601A1 (enExample)
EP (1) EP4153164A4 (enExample)
JP (1) JP2023527153A (enExample)
KR (1) KR20230015939A (enExample)
CN (1) CN115916181A (enExample)
AU (1) AU2021273936A1 (enExample)
BR (1) BR112022022737A2 (enExample)
CA (1) CA3195103A1 (enExample)
MX (1) MX2022014575A (enExample)
TW (1) TW202210081A (enExample)
WO (1) WO2021237143A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018026781A1 (en) 2016-08-02 2018-02-08 Virginia Commonwealth University Compositions comprising 5-cholesten-3, 25-diol, 3-sulfate (25hc3s) or pharmaceutically acceptable salt thereof and at least one cyclic oligosaccharide

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI20848A (sl) * 2001-03-14 2002-10-31 Lek, Tovarna Farmacevtskih In Kemijskih Izdelkov, D.D. Farmacevtska formulacija, ki vsebuje atorvastatin kalcij
WO2006047022A1 (en) * 2004-10-25 2006-05-04 Virginia Commonwealth University Nuclear sulfated oxysterol, potent regulator of cholesterol homeostasis, for therapy of hypercholesterolemia, hyperlipidemia, and atherosclerosis
US8399441B2 (en) * 2004-10-25 2013-03-19 Virginia Commonwealth University Nuclear sulfated oxysterol, potent regulator of lipid homeostasis, for therapy of hypercholesterolemia, hypertriglycerides, fatty liver diseases, and atherosclerosis
US9034859B2 (en) * 2011-04-06 2015-05-19 Virginia Commonwealth University Sulfated oxysterol and oxysterol sulfation by hydroxysterol sulfotransferase promote lipid homeostasis and liver proliferation
JP6185473B2 (ja) * 2011-09-16 2017-08-23 ガレクティン・セラピューティクス・インコーポレイテッドGalectin Therapeutics, Inc. 非アルコール性脂肪性肝炎および非アルコール性脂肪肝疾患を処置するためのガラクト−ラムノガラクツロネート組成物
CN105592846A (zh) * 2013-03-15 2016-05-18 持田制药株式会社 用于治疗非酒精性脂肪性肝炎的组合物和方法
WO2018026781A1 (en) * 2016-08-02 2018-02-08 Virginia Commonwealth University Compositions comprising 5-cholesten-3, 25-diol, 3-sulfate (25hc3s) or pharmaceutically acceptable salt thereof and at least one cyclic oligosaccharide
KR102462275B1 (ko) * 2016-08-02 2022-11-01 듀렉트 코퍼레이션 산소화 콜레스테롤 술페이트, 및 폴리알킬렌 글리콜, 카르복시메틸 셀룰로오스 및 폴리옥실글리세리드 중 적어도 하나를 포함하는 조성물
MX2019012535A (es) * 2017-04-18 2020-08-17 Genfit Combinacion que comprende un agonista de ppar tal como elafibranor y un inhibidor de la acetil-coa carboxilasa (acc).
JP7479278B2 (ja) * 2017-10-06 2024-05-08 ギリアード サイエンシーズ, インコーポレイテッド Acc阻害剤を含む併用療法

Similar Documents

Publication Publication Date Title
CN102526733B (zh) 用于预防心血管事件发病的组合物
AU732465B2 (en) Combination therapy for reducing the risks associated with cardiovascular disease
US4997658A (en) Method for enhancing the lowering of plasma cholesterol levels
US6673831B1 (en) Combination therapy for reducing the risks associated with cardiovascular disease
WO2001068096A2 (en) Combination therapy for the prophylaxis and treatment of hyperlipidemic conditions and disorders
JP2008291034A (ja) コレステロール吸収阻害剤、HMG−CoAレダクターゼ阻害剤および安定化剤を含有する組成物
CN1330544A (zh) 色伐他丁与贝特的组合
CA2456732A1 (en) Oral pharmaceutical composition containing a combination of ppar.alpha. and a hmg-coa reductase inhibitor
IL274414B1 (en) Oral rifamycin sv compositions
CN102264346A (zh) 用于通过颊透粘膜途径来施用降血脂药的制剂
JP2009515816A (ja) フェノフィブレートおよびスタチンを含んでなる新規調合物、ならびに関連する処置方法
US20050187204A1 (en) Medicinal composition for lowering blood lipid level
JPWO2021237143A5 (enExample)
US20140314844A1 (en) Oral complex formulation comprising omega-3 fatty acid and hmg-coa reductase inhibitor with improved stability
JPWO2021237146A5 (enExample)
US6890941B1 (en) Compositions containing HMG Co-A reductase inhibitors and policosanol
TWI302457B (en) A pharmaceutical composition for improving blood lipid or reducing blood homocysteine
JP2007534731A5 (enExample)
WO2020028124A1 (en) NEW USE OF CARBAMATE β PHENYLETHANOLAMINE ANALOGUES FOR ENHANCING INTRACELLULAR CLEARANCE OF LDL CHOLESTEROL AND FOR COMBINING THERAPY WITH STATINS TO ENHANCE THE EFFICACY AND REDUCE ADVERSE EFFECTS
WO2004080488A2 (de) Kombinationspräparate von acetylsalicylsäure mit einem hmg-coa-reduktase
JPWO2022177428A5 (enExample)
CA2480275A1 (en) Statin therapy for enhancing cognitive maintenance
RU2007149337A (ru) Новый способ лечения гиперлипидемии
CN1546017A (zh) 奥利司他的复方制剂
US20050182036A1 (en) Medicinal composition containing an HMG-CoA reductase inhibitor